Powered by Bravenet Bravenet Blog

Wednesday, March 26th 2008

6:22 AM

Research Finds That Calorie Use May Be Accelerated at Mitochondrial Level

Fats and carbohydrates are used by mitochondria, the energy factories
inside cells. When muscles contract and for many other cellular
processes, this energy used up. In some cases, such as when exposed to
cold, not all the energy released from sugars and fats is used to move
muscles, some is burned to warm the body. This phenomenon is known as
mitochondrial uncoupling. Carbohydrates and fats are still used up in the uncoupled
mitochondria, but the energy released
is not entirely used for moving muscles. More energy is used up to carry
out the same physical functions.
Read it HERE
0 Comment(s) / Post Comment

Tuesday, March 25th 2008

11:09 PM

New Gene Study Demonstrates How Genetics Influence Obesity

Regulation of common metabolism pathways by different genes plays a important role determining your chances of becoming obese or developing common diseases such as type II diabetes,The fact that changes in the obesity gene carry a comparable risk of obesity in both children and adults, suggests that this gene mutation may be associated with obesity starting in childhood.  Medical researchers hope to treat patients by targeting this specific gene for obesity.

Read Story HERE

0 Comment(s) / Post Comment

Tuesday, March 25th 2008

10:42 PM

Obesity surgery Provides to Cardiac Benefits

Bariatric surgery is an accepted intervention for class II-III obesity, and appears to result in improved risk for cardiac disease. In a study presented today at the American College of Cardiology's Annual Meeting,  Mayo Clinic researchers looked the effects of bariatric surgery on longterm cardiac disease and evaluated outcomes.The study showed that the percentage of the surgery patients withdiabetes was reduced from 30 percent to 11 percent, they also showed reductions in hypertesion, as well as  LDL (bad)cholesterol and Body Mass Index.

Technorati Profile
0 Comment(s) / Post Comment

Tuesday, March 25th 2008

10:23 PM

Locaserin a New Obesity Drug Passes Safety Tests

The new obesity drug lorcaserin is in  Phase 3 (final stage) trials, which are  double-blind, randomized, drug trials with 3,200 patients in 100 centers in the United States. Echocardiograms were done to make sure that the new drug had no adverse effects on heart valves and so far it looks safe. Locaserin is the first in a new class of obesity drugs that target the 5-HT2C serotonin receptor,  located in the hypothalamus, which regulates food intake and metabolism. The results from the Phase 2 studies showed that  lorcaserin produced highly statistically significant, progressive weight loss over a 12-weeks. Lorcaserin was well tolerated at all doses in the Phase 2 drug trials and had no apparent effects on the heart valves or on thepulmonary artery pressure

Read More HERE
0 Comment(s) / Post Comment